Compare Lucid Group Inc (LCID) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lucid Group Inc vs BIO-TECHNE Corp — how do they compare? Lucid Group Inc trades at $7.19 (market cap $2.77B), while BIO-TECHNE Corp trades at $71.71 (market cap $11.16B). The key difference: BIO-TECHNE Corp is far larger — about 4× Lucid Group Inc's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Lucid Group Inc pays none. Which is the better fit depends on your goals.
| LCID | TECH | |
|---|---|---|
Market Cap | $2.77B | $11.16B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.30 | $72.12 |
52-Week Low | $4.62 | $43.31 |
Enterprise Value | $5.24B | $11.24B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lucid Group (LCID) trades at $7.33, down 0.41% on the day, amid mixed technical signals and severe fundamental challenges. The stock shows a bullish moving average trend but bearish oscillators, with RSI at 70.77 suggesting overbought conditions. Financially, the company reported a net loss of $2.70 billion on $1.35 billion revenue in 2025, with negative margins across gross profit (-95.6%) and net income (-239.81%). Recent news highlights class-action lawsuits and bankruptcy rumors, though management denies financial distress.
The outlook remains highly speculative with significant execution and liquidity risks. Analyst consensus is cautious, with 66.7% hold ratings and a $10.50 price target implying limited upside. Investment appeal hinges on Lucid's ability to achieve profitability and scale production, but current financials and legal overhangs present substantial headwinds for near-term performance.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
